transmembrane protein 236Genealiases: FAM23A · FAM23B · bA162I21.2 · bA16O1.2
Q-omics provides the consensus-scored TMEM236 profile across patient tissues and cancer cell-line models. TMEM236 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TMEM236 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TMEM236 RNA expression shows 16,228 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, COAD, and UVM as cancer lineages where TMEM236 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM236 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM236 survival associations across molecular data types. TMEM236 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM236 RNA expression–survival associations across cancer types. High TMEM236 expression shows unfavorable associations in LUSC, UVM and STAD, but favorable associations in SKCM, BLCA and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TMEM236 RNA expression.
This table summarizes TMEM236 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM236. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM236 shows lower tumor expression in COAD, KICH, LUSC and LUAD and higher tumor expression in HNSC and THCA. The COAD box plot shows higher TMEM236 RNA expression in normal versus tumor tissue (log2 FC = −3.700, t-test p < 0.001).
This table shows molecular features associated with TMEM236 in patient tissues and cancer cell lines. In patient samples, TMEM236 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM236 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
